Pricing Log in Create free account

Belite Bio, Inc. Sponsored ADR (BLTE) vs CG Oncology, Inc. (CGON)

Belite Bio, Inc. Sponsored ADR and CG Oncology, Inc. are both Biotechnology companies. Belite Bio, Inc. Sponsored ADR is the larger, with a market value of $6.2B against $5.5B — 1.1× the size. Belite Bio, Inc. Sponsored ADR has the higher net margin (0.00% vs −3,602.7%) and the higher return on invested capital (−9.55% vs −4,111.6%). Across the 13 metrics below, Belite Bio, Inc. Sponsored ADR leads on 10 and CG Oncology, Inc. on 3.

Valuation

Metric BLTE CGON Biotechnology median
P/E n/m n/m 8.50
P/S n/m 846.74 9.71
P/B 7.45 5.12 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 683.55 9.21
Earnings yield (1.91%) (4.50%) (33.15%)
Free cash flow yield (1.16%) (3.40%) (25.50%)

Profitability

Metric BLTE CGON Biotechnology median
Gross margin — (85.20%) 65.16%
Operating margin 0.00% (4,056.18%) 0.00%
Net margin 0.00% (3,602.68%) 0.00%
Free cash flow margin 0.00% (2,879.62%) 0.00%
Return on equity 0.00% (26.41%) (56.36%)
Return on assets (21.60%) (25.11%) (48.04%)
Return on invested capital (9.55%) (4,111.64%) 0.00%

Growth

Metric BLTE CGON Biotechnology median
Revenue growth (TTM) — 840.79% 6.02%
EPS growth (last fiscal year) (95.76%) (47.52%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric BLTE CGON Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 33.56 22.22 4.72
Net debt to EBITDA 5.88 3.88 0.96

Dividend

Metric BLTE CGON Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BLTE CGON Biotechnology median
Market cap 6.15b 5.48b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack